Share on StockTwits

Gilead Sciences (NASDAQ:GILD) EVP Gregg H. Alton sold 33,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $108.58, for a total value of $3,583,140.00. Following the transaction, the executive vice president now directly owns 122,694 shares in the company, valued at approximately $13,322,115. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

GILD has been the subject of a number of recent research reports. Analysts at RBC Capital raised their price target on shares of Gilead Sciences from $102.00 to $115.00 in a research note on Friday, August 22nd. They now have an “outperform” rating on the stock. Separately, analysts at Cowen and Company raised their price target on shares of Gilead Sciences from $95.00 to $105.00 in a research note on Friday, August 15th. They now have an “outperform” rating on the stock. One investment analyst has rated the stock with a hold rating and twenty-one have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $105.55.

Gilead Sciences (NASDAQ:GILD) traded down 2.35% on Thursday, hitting $106.86. 13,763,401 shares of the company’s stock traded hands. Gilead Sciences has a one year low of $58.81 and a one year high of $110.64. The stock has a 50-day moving average of $96.38 and a 200-day moving average of $83.42. The company has a market cap of $161.5 billion and a P/E ratio of 24.79. Gilead Sciences also was the recipient of a large decrease in short interest during the month of August. As of August 15th, there was short interest totalling 90,068,658 shares, a decrease of 8.5% from the July 31st total of 98,473,543 shares. Currently, 5.9% of the shares of the company are short sold. Based on an average daily volume of 11,565,205 shares, the days-to-cover ratio is presently 7.8 days.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, July 23rd. The company reported $2.36 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.73 by $0.63. The company had revenue of $6.53 billion for the quarter, compared to the consensus estimate of $5.68 billion. During the same quarter in the prior year, the company posted $0.50 earnings per share. The company’s quarterly revenue was up 136.1% on a year-over-year basis. On average, analysts predict that Gilead Sciences will post $8.01 earnings per share for the current fiscal year.

Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.

Receive News & Ratings for Gilead Sciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.